Myelodysplastic Syndromes (MDS): Risk Factors, Treatment and Prognosis

Deanna Rodgers (Editor)

Series: Recent Advances in Hematology Research
BISAC: MED038000

Clear

$210.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Myelodysplastic syndrome (MDS) is a family of clonal haematopoietic stem cells disorders characterized by dysplasia, ineffective hematopoiesis and susceptibility to transformation to Acute Myeloblastic Leukaemia (AML) that are shown to be strikingly refractory to current therapeutic modalities. The first chapter of this book provides a detailed review of the risk factors, treatment options and prognosis of MDS. Chapter two studies the inflammatory and autoimmune nature of MDS. Chapter three discusses the pathogenesis of 5q-syndrome. Chapter four examines the genetic mutations identified in MDS and their significance.

Chapter five reviews different prognostic factors and stratifications of risk in Argentinean patients with MDS. Chapter six discusses epigenetics and epigenetic therapy. Chapter seven introduces mild oral chemotherapy treatments for elderly patients with a higher-risk myelodyspastic syndrome. Chapter eight discusses lenalidomide treatment in lower risk myelodysplastic syndromes. Chapter nine analyzes the old and new-integrating prognostic models and mutational advances with epigenetic and cellular therapies for MDS. The last chapter studies the entropy evaluation of bone marrow biopsies in MDS.
(Imprint: Nova Biomedical)

Preface

Chapter 1
From Risk factors to Prognosis in Myelodysplasic Syndromes: The Role of Genetic Variance
(Ana Bela Sarmento-Ribeiro, André Barbosa Ribeiro, Emília Nobre Barata Roxo Cortesão, José Manuel Nascimento Costa, Oncobiology and Hematology Lab, University Clinic of Haematology and Applied Molecular Biology, Faculty of Medicine, University of Coimbra - Coimbra, Portugal, and others)

Chapter 2
The Inflammatory and Autoimmune Nature of Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Chapter 3
Pathogenesis of 5q- Syndrome
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Chapter 4
Genetic Mutations Identified in Myelodysplastic Syndromes and Their Significance
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Chapter 5
Risk Factors and Prognostic Scoring Systems in Argentinean Patients with MDS: A Multicentric Study
(Carolina B. Belli, Jacqueline Gonzalez, Virna Barcalá, Marcela de Dios Soler, Marcelo Iastrebner, and María Gabriela Flores, Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/ ANM, Academia Nacional de Medicina, Buenos Aires, Argentina, and others)

Chapter 6
Epigenetics and Epigenetic Therapy of Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Chapter 7
Introduction of Mild Oral Chemotherapy for Elderly Patients with Higher-Risk Myelodysplastic Syndromes
(Akira Horikoshi, Department of General Internal Medicine, Nerima-Hikarigaoka Hospital, Japan)

Chapter 8
Lenalidomide Treatment in Lower Risk Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Chapter 9
The Old and The New-Integrating Prognostic Models and Mutational Advances with Epigenetic and Cellular Therapies for Myelodysplastic Syndromes
(Uma Borate and Antonio Di Stasi, The University of Alabama at Birmingham, Birmingham, AL, USA)

Chapter 10
Entropy Evaluation of Bone Marrow Biopsies in Myelodysplastic Syndromes
(Giorgio Bianciardi, and Pietro Luzi, Dept. of Medical biotechnologies, Anatomia Patologica, Siena University, Siena, Italy, and others)

Index

You have not viewed any product yet.